Generation of Ramoplanin-resistant Staphylococcus Aureus

Overview

Journal FEMS Microbiol Lett

Publisher Oxford University Press

Specialty Microbiology

Date 2010 Jul 28

PMID 20659164

Citations 9

Authors

John W Schmidt

Adrienne Greenough

Michelle Burns

Andrea E Luteran

Dewey G McCafferty

Affiliations

Soon will be listed here.

Abstract

Ramoplanin is a lipoglycodepsipeptide antimicrobial active against clinically important Gram-positive bacteria including methicillin-resistant Staphylococcus aureus. To proactively examine ramoplanin resistance, we subjected S. aureus NCTC 8325-4 to serial passage in the presence of increasing concentrations of ramoplanin, generating the markedly resistant strain RRSA16. Susceptibility testing of RRSA16 revealed the unanticipated acquisition of cross-resistance to vancomycin and nisin. RRSA16 displayed phenotypes, including a thickened cell wall and reduced susceptibility to Triton X-100-induced autolysis, which are associated with vancomycin intermediate-resistant S. aureus strains. Passage of RRSA16 for 18 days in a drug-free medium yielded strain R16-18d with restored antibiotic susceptibility. The RRSA16 isolate may be used to identify the genetic and biochemical basis for ramoplanin resistance and to further our understanding of the evolution of antibiotic cross-resistance mechanisms in S. aureus.

Citing Articles

Fighting Antimicrobial Resistance: Innovative Drugs in Antibacterial Research.

Sussmuth R, Sussmuth R, Kulike-Koczula M, Kulike-Koczula M, Gao P, Kosol S Angew Chem Int Ed Engl. 2024; 64(10):e202414325.

PMID: 39611429 PMC: 11878372. DOI: 10.1002/anie.202414325.

An extensively validated whole-cell biosensor for specific, sensitive and high-throughput detection of antibacterial inhibitors targeting cell-wall biosynthesis.

Galarion L, Mitchell J, Randall C, ONeill A J Antimicrob Chemother. 2023; 78(3):646-655.

PMID: 36626387 PMC: 9978594. DOI: 10.1093/jac/dkac429.

Phenotypic convergence of bacterial adaption to sub-lethal antibiotic treatment.

Wee G, Lyou E, Hong J, No J, Kim S, Lee T Front Cell Infect Microbiol. 2022; 12:913415.

PMID: 36467735 PMC: 9714565. DOI: 10.3389/fcimb.2022.913415.

is able to generate resistance to novel lipoglycopeptide antibiotic gausemycin A.

Poshvina D, Dilbaryan D, Kasyanov S, Sadykova V, Lapchinskaya O, Rogozhin E Front Microbiol. 2022; 13:963979.

PMID: 36246291 PMC: 9558223. DOI: 10.3389/fmicb.2022.963979.

Antimicrobial Resistance Phenotype of and Isolates Obtained from Meat in the Formal and Informal Sectors in South Africa.

Jaja I, Jaja C, Chigor N, Anyanwu M, Maduabuchi E, Oguttu J Biomed Res Int. 2020; 2020:3979482.

PMID: 33015163 PMC: 7525293. DOI: 10.1155/2020/3979482.

References

Cui L, Iwamoto A, Lian J, Neoh H, Maruyama T, Horikawa Y . Novel mechanism of antibiotic resistance originating in vancomycin-intermediate Staphylococcus aureus. Antimicrob Agents Chemother. 2006; 50(2):428-38. PMC: 1366884. DOI: 10.1128/AAC.50.2.428-438.2006. View

Bozdogan B, Esel D, Whitener C, Browne F, Appelbaum P . Antibacterial susceptibility of a vancomycin-resistant Staphylococcus aureus strain isolated at the Hershey Medical Center. J Antimicrob Chemother. 2003; 52(5):864-8. DOI: 10.1093/jac/dkg457. View

Cui L, Murakami H, Kuwahara-Arai K, Hanaki H, Hiramatsu K . Contribution of a thickened cell wall and its glutamine nonamidated component to the vancomycin resistance expressed by Staphylococcus aureus Mu50. Antimicrob Agents Chemother. 2000; 44(9):2276-85. PMC: 90058. DOI: 10.1128/AAC.44.9.2276-2285.2000. View

Mobarakai N, Quale J, Landman D . Bactericidal activities of peptide antibiotics against multidrug-resistant Enterococcus faecium. Antimicrob Agents Chemother. 1994; 38(2):385-7. PMC: 284464. DOI: 10.1128/AAC.38.2.385. View

Nam J, Shin D, Rew Y, Boger D . Alanine scan of [L-Dap(2)]ramoplanin A2 aglycon: assessment of the importance of each residue. J Am Chem Soc. 2007; 129(28):8747-55. PMC: 2593884. DOI: 10.1021/ja068573k. View

Breukink E, Wiedemann I, van Kraaij C, Kuipers O, Sahl H, de Kruijff B . Use of the cell wall precursor lipid II by a pore-forming peptide antibiotic. Science. 1999; 286(5448):2361-4. DOI: 10.1126/science.286.5448.2361. View

Biavasco F, Manso E, Varaldo P . In vitro activities of ramoplanin and four glycopeptide antibiotics against clinical isolates of Clostridium difficile. Antimicrob Agents Chemother. 1991; 35(1):195-7. PMC: 244968. DOI: 10.1128/AAC.35.1.195. View

NOVICK R . Properties of a cryptic high-frequency transducing phage in Staphylococcus aureus. Virology. 1967; 33(1):155-66. DOI: 10.1016/0042-6822(67)90105-5. View

Neoh H, Cui L, Yuzawa H, Takeuchi F, Matsuo M, Hiramatsu K . Mutated response regulator graR is responsible for phenotypic conversion of Staphylococcus aureus from heterogeneous vancomycin-intermediate resistance to vancomycin-intermediate resistance. Antimicrob Agents Chemother. 2007; 52(1):45-53. PMC: 2223914. DOI: 10.1128/AAC.00534-07. View

10.

BROTZ H, Josten M, Wiedemann I, Schneider U, Gotz F, Bierbaum G . Role of lipid-bound peptidoglycan precursors in the formation of pores by nisin, epidermin and other lantibiotics. Mol Microbiol. 1998; 30(2):317-27. DOI: 10.1046/j.1365-2958.1998.01065.x. View

11.

Mani N, Tobin P, Jayaswal R . Isolation and characterization of autolysis-defective mutants of Staphylococcus aureus created by Tn917-lacZ mutagenesis. J Bacteriol. 1993; 175(5):1493-9. PMC: 193237. DOI: 10.1128/jb.175.5.1493-1499.1993. View

12.

Cudic P, Kranz J, Behenna D, Kruger R, Tadesse H, Wand A . Complexation of peptidoglycan intermediates by the lipoglycodepsipeptide antibiotic ramoplanin: minimal structural requirements for intermolecular complexation and fibril formation. Proc Natl Acad Sci U S A. 2002; 99(11):7384-9. PMC: 124240. DOI: 10.1073/pnas.102192099. View

13.

Peschel A, Otto M, JACK R, Kalbacher H, Jung G, Gotz F . Inactivation of the dlt operon in Staphylococcus aureus confers sensitivity to defensins, protegrins, and other antimicrobial peptides. J Biol Chem. 1999; 274(13):8405-10. DOI: 10.1074/jbc.274.13.8405. View

14.

Wiegand I, Hilpert K, Hancock R . Agar and broth dilution methods to determine the minimal inhibitory concentration (MIC) of antimicrobial substances. Nat Protoc. 2008; 3(2):163-75. DOI: 10.1038/nprot.2007.521. View

15.

Sieradzki K, Tomasz A . Inhibition of cell wall turnover and autolysis by vancomycin in a highly vancomycin-resistant mutant of Staphylococcus aureus. J Bacteriol. 1997; 179(8):2557-66. PMC: 179004. DOI: 10.1128/jb.179.8.2557-2566.1997. View

16.

CHATTERJEE A, Wong W, Young F, Gilpin R . Isolation and characterization of a mutant of Staphylococcus aureus deficient in autolytic activity. J Bacteriol. 1976; 125(3):961-7. PMC: 236172. DOI: 10.1128/jb.125.3.961-967.1976. View

17.

Cui L, Neoh H, Shoji M, Hiramatsu K . Contribution of vraSR and graSR point mutations to vancomycin resistance in vancomycin-intermediate Staphylococcus aureus. Antimicrob Agents Chemother. 2009; 53(3):1231-4. PMC: 2650561. DOI: 10.1128/AAC.01173-08. View

18.

Lu J, Lee S, Hwa S, Yang A . Septic arthritis caused by vancomycin-intermediate Staphylococcus aureus. J Clin Microbiol. 2005; 43(8):4156-8. PMC: 1233910. DOI: 10.1128/JCM.43.8.4156-4158.2005. View

19.

Sass P, Bierbaum G . Native graS mutation supports the susceptibility of Staphylococcus aureus strain SG511 to antimicrobial peptides. Int J Med Microbiol. 2009; 299(5):313-22. DOI: 10.1016/j.ijmm.2008.10.005. View

20.

Jones R, Barry A . In vitro evaluation of ramoplanin (A16686 or MDL62198). A new depsipeptide complex for potential topical use. Diagn Microbiol Infect Dis. 1989; 12(3):279-82. DOI: 10.1016/0732-8893(89)90029-1. View